Sci. Signal., 22 May 2012
Science Signaling Podcast: 22 May 2012
Mari L. Shinohara1,2 and Annalisa M. VanHook3
1 Department of Immunology, Duke University Medical Center, Durham, NC 27710, USA.
Abstract: This Podcast features an interview with Mari Shinohara, senior author of a Research Article published in the 22 May 2012 issue of Science Signaling. Interferon-β (IFN-β) treatment can slow the progression of multiple sclerosis (MS) by reducing inflammation in the nervous system, but it is not effective in all patients. Mari Shinoharas group studies the effects of IFN-β therapy in a mouse model of MS to understand how this protein can inhibit the inflammation that leads to neurological dysfuntion in human patients. They found that IFN-β therapy is only effective in treating symptoms in the mouse model when development of the disease depends upon the NLRP3 inflammasome, suggesting the possibility that this might also be the reason for the failure of IFN-β therapy in some human MS patients.
Citation: M. L. Shinohara, A. M. VanHook, Science Signaling Podcast: 22 May 2012. Sci. Signal. 5, pc11 (2012).
The editors suggest the following Related Resources on Science sites:
In Science Signaling
Science Signaling. ISSN 1937-9145 (online), 1945-0877 (print). Pre-2008: Science's STKE. ISSN 1525-8882